"What have we seen in the past that tells us CD can be improved,...?"

There are not easily measurable things like changes eGFR in CKD to look for in the cognition/neurodegenerative disease research. However, here are some past presentations and posters that cover the rationale.

Cognitive Evaluation of Treatment Effects of the Bromodomain Inhibitor Apabetalone: Baseline Data of the Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial

https://www.resverlogix.com/upload/event/42/4388386bbd26/2019-03-29---ad-pd-2019-cummings-final.pdf

Effects of the Epigenetic BET-Inhibitor Small Molecule Apabetalone on Cognition in Patients with Diabetes and Cardiovascular Disease

https://www.resverlogix.com/upload/media_element/173/b9738b92dd21/2019-07-08---aaic-poster-2019-final.pdf

Epigenetic Inhibitor Apabetalone Downregulates Brain Endothelial and Microglial Cell Activation that Contributes To Neurodegenerative Disease

https://www.resverlogix.com/upload/media_element/164/c6c479d2184e/ad-pd-2019-poster-final.pdf

Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia and Vascular Endothelial Cells that Contribute to Neurodegenerative Disease.

https://www.resverlogix.com/upload/media_element/144/aa9c9bf7caa6/ctad-europe-poster-2018.pdf

Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients.

https://www.resverlogix.com/upload/media_element/133/e5b96eae2f32/2018-08-27-ctad-asia-poster.pdf

Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia that Contribute to Neurodegenerative Disease.

https://www.resverlogix.com/upload/media_element/attachments/23/AD%20PD%202017%20Poster.pdf